Medical Devices Series B Investors & VC Firms
515 firms in this list, with a median first check of $540K. 108 of them lead rounds. Generated from verified public data and updated continuously.
Pointguard Ventures
Los AltosSeries A–Series B$2M – $10M
5 people
Orbia Ventures
BostonSeed–Series B$1M – $6M
6 people
Shenzhen Capital Group
ShenzhenSeed–Growth$1M – $3.5M
3 people
NYBC Ventures
New YorkSeed–Series B
8 people
Avego BioScience Capital
AlpharettaSeries A–Late Stage
2 people
Criteria Bio Ventures
BarcelonaSeed–Series B
7 people
New Leaf Venture Partners
New YorkSeed–Series B
7 people
Cycad Group LLC
Santa BarbaraSeed–Late Stage
4 people
IAG Capital Partners
CharlestonSeed–Growth
4 people
Launch Capital
TorontoSeed–Series B
3 people
Montis Capital
WarsawSeries A–Growth$1.6M – $5.5M
4 people
Target Partners
MunichSeed–Late Stage$1.1M – $3.2M
7 people
Toledo Capital AG
ZürichSeed–Late Stage
12 people
JJDC
New BrunswickSeed–Series B$500K – $5M
11 people
Sectoral Asset Management
MontrealSeries B–Late Stage
8 people
Vertex Ventures HC
SingaporeSeed–Growth$500K – $10M
4 people
Vesalius Biocapital Partners
LuxembourgSeed–Growth$11M
5 people
ExSight Ventures
New YorkPre-Seed–Series B
4 people
Pandect Bioventures
WoodsideSeed–Late Stage
10 people
Clal Biotechnology Industries
Tel AvivSeed–Late Stage
8 people
Excelestar Ventures
AndoverSeed–Series B
2 people
Kendall Capital Partners
BostonSeed–Growth
7 people
Ming capital
ShenzhenSeed–Series C
6 people
SBI JI Innovation Advisory Ltd.
Tel Aviv-YafoSeed–Series B
6 people
Related lists
Series B Investors & VC Firms (2954)Series B Investors & VC Firms in North America (1744)Medical Devices Investors & VC Firms (1659)Series B Investors & VC Firms in United States (1578)Medical Devices Seed Investors & VC Firms (1321)Medical Devices Series A Investors & VC Firms (1139)Medical Devices Investors & VC Firms in North America (1090)Series B Investors & VC Firms in Europe (1078)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Global (1068)
Data sourced from public filings and firms' own websites — see our methodology.










































































